Loading...
Market
What will be the FDA's decision on Wegovy for MASH treatment by end of 2025?
2
Resolution / Starting Odds
Approved for MASH treatment • 25%
Approved with conditions • 25%
Not approved • 25%
Decision delayed • 25%
FDA official announcements and press releases
Story
Novo Nordisk to Seek FDA Approval for Wegovy in Treating MASH After New Data on Liver Fibrosis
Nov 1, 2024, 02:21 PM
Novo Nordisk announced plans to file for FDA approval of Wegovy to treat Metabolic Associated Steatotic Hepatitis (MASH), previously known as fatty liver disease. The decision follows the release of new data indicating the drug's potential benefits beyond weight loss. However, the data does not demonstrate improvement in liver fibrosis, a key metric where Madrigal Pharmaceuticals' Rezdiffra has shown success after its approval earlier this year. Analysts noted that while the Wegovy data is not groundbreaking, it remains significant and could warrant an update to the drug's labeling.
View original story
Similar markets
United States • 25%
European Union • 25%
China • 25%
Other • 25%
Less than 60% • 25%
60% to 70% • 25%
70% to 80% • 25%
More than 80% • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Significant increase (>10%) • 25%
Moderate increase (5-10%) • 25%
No significant change • 25%
Decrease • 25%
Approved for all indications • 25%
Approved for some indications • 25%
Not approved • 25%
Approval delayed • 25%
